AnaptysBio, Inc. (ANAB)
Stock Price:
$20.33 USD
0.17 (0.82%)
Updated Jul 14, 2020 12:30 PM EDT - Market open
Key Info
| Market Cap |
554.41M |
| Revenue (ttm) |
23.00M |
| Net Income (ttm) |
-83.52M |
| Shares Out |
27.28M |
| EPS (ttm) |
-3.08 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 14, 2020 |
| Last Price |
$20.33 |
| Previous Close |
$20.16 |
| Change ($) |
0.17 |
| Change (%) |
0.82% |
| Day's Open |
20.16 |
| Day's Range |
19.87 - 20.75 |
| Day's Volume |
111,012 |
| 52-Week Range |
10.00 - 56.72 |
More Stats
| Market Cap |
554.41M |
| Enterprise Value |
191.86M |
| Earnings Date (est) |
Aug 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
27.28M |
| Float |
16.08M |
| EPS (basic) |
-3.09 |
| EPS (diluted) |
-3.08 |
| FCF / Share |
-2.54 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
5.12M |
| Short Ratio |
11.29 |
| Short % of Float |
28.83% |
| Beta |
0.93 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
24.10 |
| PB Ratio |
1.53 |
| Revenue |
23.00M |
| Operating Income |
-92.91M |
| Net Income |
-83.52M |
| Free Cash Flow |
-69.24M |
| Net Cash |
362.54M |
| Net Cash / Share |
13.29 |
| Gross Margin |
-397.12% |
| Operating Margin |
-403.97% |
| Profit Margin |
-363.10% |
| FCF Margin |
-301.05% |
| ROA |
-12.65% |
| ROE |
-19.23% |
| ROIC |
-32.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (7)
| Buy |
1 |
| Overweight |
0 |
| Hold |
5 |
| Underweight |
0 |
| Sell |
1 |
Price Target
$18.67*
(-8.14% downside)
Low
16.0
Current: 20.33
High
28.0
Target: 18.67
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | 8.00 | 5.00 | 10.00 | 16.68 | 17.57 | 15.84 |
| Revenue Growth | 60% | -50% | -40.06% | -5.05% | 10.94% | - |
| Gross Profit | 8.00 | 5.00 | 10.00 | 16.68 | 17.57 | 15.84 |
| Operating Income | -107 | -66.72 | -28.78 | -3.03 | -3.32 | 4.87 |
| Net Income | -97.34 | -61.66 | -30.07 | -4.26 | -5.41 | 3.53 |
| Shares Outstanding | 27.06 | 24.67 | 19.78 | 2.64 | 2.55 | 2.48 |
| Earnings Per Share | -3.60 | -2.50 | -1.52 | -1.62 | -2.12 | 0.09 |
| Operating Cash Flow | -69.52 | -48.51 | -19.44 | -9.03 | -9.69 | 14.60 |
| Capital Expenditures | -0.81 | -1.06 | -0.29 | -0.05 | -0.24 | -0.14 |
| Free Cash Flow | -70.32 | -49.57 | -19.73 | -9.08 | -9.93 | 14.46 |
| Cash & Equivalents | 374 | 427 | 248 | 51.29 | 51.74 | 0.00 |
| Total Debt | 1.38 | 7.57 | 14.43 | 13.81 | 4.90 | - |
| Net Cash / Debt | 373 | 420 | 234 | 37.48 | 46.84 | 0.00 |
| Assets | 435 | 509 | 329 | 62.18 | 56.28 | - |
| Liabilities | 30.19 | 22.63 | 21.78 | 100 | 91.46 | - |
| Book Value | 405 | 486 | 308 | -38.25 | -35.18 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
AnaptysBio, Inc. |
| Country |
United States |
| Employees |
89 |
| CEO |
Hamza Suria |
Stock Information
| Ticker Symbol |
ANAB |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ANAB |
| IPO Date |
January 26, 2017 |
Description
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor for generalized pustular psoriasis and palmoplantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd.; and collaboration with Celgene Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California.